

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-60 (Canceled)

61. (New) A method of ameliorating hepatic steatosis in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) and inhibits the expression of apolipoprotein C-III so that hepatic steatosis is ameliorated.
62. (New) The method of Claim 61, wherein the hepatic steatosis is steatohepatitis.
63. (New) The method of Claim 61, wherein the hepatic steatosis is non-alcoholic steatohepatitis.
66. (New) The method of Claim 61, wherein said antisense compound comprises an oligonucleotide.
67. (New) The method of Claim 66, wherein said oligonucleotide comprises a single-stranded nucleotide.
68. (New) The method of Claim 67, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.
69. (New) The method of Claim 68, wherein said modified internucleoside linkage is a phosphorothioate linkage.
70. (New) The method of Claim 68, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
71. (New) The method of Claim 68, wherein said modified nucleobase is a 5-methylcytosine.
72. (New) A method of lowering liver tissue triglyceride levels in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule

encoding apolipoprotein C-III (SEQ ID NO: 4), wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby lowers liver tissue triglyceride levels.

73. (New) The method of Claim 72, wherein said antisense compound comprises an oligonucleotide.

74. (New) The method of Claim 73, wherein said oligonucleotide comprises a single-stranded nucleotide.

75. (New) The method of Claim 74, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

76. (New) The method of Claim 75, wherein said modified internucleoside linkage is a phosphorothioate linkage.

77. (New) The method of Claim 75, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

78. (New) The method of Claim 75, wherein said modified nucleobase is a 5-methylcytosine.

79. (New) A method of reducing adipose tissue in an animal comprising administering to said animal a therapeutically effective amount of an antisense compound that specifically hybridizes with a nucleic acid molecule encoding apolipoprotein C-III (SEQ ID NO: 4) wherein said antisense compound inhibits the expression of apolipoprotein C-III and thereby reduces adipose tissue.

80. (New) The method of Claim 79, wherein said antisense compound comprises an oligonucleotide.

81. (New) The method of Claim 80, wherein said oligonucleotide comprises a single-stranded nucleotide.

82. (New) The method of Claim 81, wherein said oligonucleotide comprises at least one modified internucleoside linkage, sugar moiety, or nucleobase.

83. (New) The method of Claim 82, wherein said modified internucleoside linkage is a phosphorothioate linkage.

84. (New) The method of Claim 82, wherein said modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

85. (New) The method of Claim 82, wherein said modified nucleobase is a 5-methylcytosine.